Characteristics | EGFR | ALK | ||||
---|---|---|---|---|---|---|
Wild-type | Mutant-type | P value | Wild-type | Mutant-type | P value | |
Age, years |  |  | 0.390 |  |  |  < 0.001 |
 Median | 61 | 60 |  | 61 | 54 |  |
 Range | 23–88 | 31–86 |  | 23–88 | 27–81 |  |
Gender |  |  |  < 0.001 |  |  | 0.337 |
 Female | 495 (72.37) | 321 (41.15) |  | 783 (56.01) | 33 (50.00) |  |
 Male | 189 (27.63) | 459 (58.85) |  | 615 (43.99) | 33 (50.00) |  |
Smoking history |  |  |  < 0.001 |  |  | 0.121 |
 Never-smoker | 345 (50.51) | 635 (81.41) |  | 930 (66.57) | 50 (75.76) |  |
 Ever-smoker | 338 (49.49) | 145 (18.59) |  | 467 (33.43) | 16 (24.24) |  |
Pathology |  |  |  < 0.001 |  |  | 0.036 |
 Adenocarcinoma | 585 (85.53) | 753 (96.54) |  | 1273 (91.06) | 65 (98.48) |  |
 Non-adenocarcinoma | 99 (14.47) | 27 (3.46) |  | 125 (8.94) | 1 (1.52) |  |
AFP | Â | Â | 0.104 | Â | Â | 1.000 |
 Negative | 538 (98.18) | 642 (99.23) |  | 1126 (98.69) | 54 (100.00) |  |
 Positive | 10 (1.82) | 5 (0.77) |  | 15 (1.31) | 0 (0.00) |  |
CEA | Â | Â | 0.014 | Â | Â | 0.060 |
 Negative | 341 (50.52) | 342 (44.07) |  | 645 (46.54) | 38 (58.46) |  |
 Positive | 334 (49.48) | 434 (55.93) |  | 741 (53.46) | 27 (41.54) |  |
CA125 |  |  |  < 0.001 |  |  | 0.164 |
 Negative | 319 (48.41) | 458 (59.87) |  | 748 (54.96) | 29 (46.03) |  |
 Positive | 340 (51.59) | 307 (40.13) |  | 613 (45.04) | 34 (53.97) |  |
CA19-9 | Â | Â | 0.031 | Â | Â | 0.530 |
 Negative | 493 (75.61) | 610 (80.37) |  | 1055 (78.32) | 48 (75.00) |  |
 Positive | 159 (24.39) | 149 (19.63) |  | 292 (21.68) | 16 (25.00) |  |
CA15-3 |  |  | 0.195 |  |  |  < 0.001 |
 Negative | 451 (75.04) | 542 (78.10) |  | 962 (77.64) | 31 (55.36) |  |
 Positive | 150 (24.96) | 152 (21.90) |  | 277 (22.36) | 25 (44.64) |  |
FERR |  |  |  < 0.001 |  |  | 0.135 |
 Negative | 210 (55.56) | 289 (68.16) |  | 471 (61.65) | 28 (73.68) |  |
 Positive | 168 (44.44) | 135 (31.84) |  | 293 (38.35) | 10 (26.32) |  |
CA72-4 | Â | Â | 0.010 | Â | Â | 0.209 |
 Negative | 289 (72.43) | 369 (79.87) |  | 630 (76.83) | 28 (68.29) |  |
 Positive | 110 (27.57) | 93 (20.13) |  | 190 (23.17) | 13 (31.71) |  |
PSA | Â | Â | 0.610 | Â | Â | 0.711 |
 Negative | 262 (91.93) | 165 (93.22) |  | 403 (92.22) | 24 (96.00) |  |
 Positive | 23 (8.07) | 12 (6.78) |  | 34 (7.78) | 1 (4.00) |  |
FPSA | Â | Â | 0.436 | Â | Â | 1.000 |
 Negative | 272 (95.44) | 166 (93.79) |  | 414 (94.74) | 24 (96.00) |  |
 Positive | 13 (4.56) | 11 (6.21) |  | 23 (5.26) | 1 (4.00) |  |
SCC |  |  |  < 0.001 |  |  | 0.178 |
 Negative | 472 (76.62) | 636 (90.34) |  | 1063 (84.23) | 45 (77.59) |  |
 Positive | 144 (23.38) | 68 (9.66) |  | 199 (15.77) | 13 (22.41) |  |
CYFRA 21-1 |  |  |  < 0.001 |  |  | 0.137 |
 Negative | 216 (35.64) | 332 (47.91) |  | 519 (41.75) | 29 (51.79) |  |
 Positive | 390 (64.36) | 361 (52.09) |  | 724 (58.25) | 27 (48.21) |  |
NSE | Â | Â | 0.034 | Â | Â | 0.472 |
 Negative | 212 (44.17) | 268 (50.85) |  | 460 (47.92) | 20 (42.55) |  |
 Positive | 268 (55.83) | 259 (49.15) |  | 500 (52.08) | 27 (57.45) |  |
TTF-1 |  |  |  < 0.001 |  |  | 0.145 |
 Negative | 129 (20.48) | 14 (2.04) |  | 140 (11.13) | 3 (5.08) |  |
 Positive | 501 (79.52) | 673 (97.96) |  | 1118 (88.87) | 56 (94.92) |  |
Napsin A |  |  |  < 0.001 |  |  | 0.401 |
 Negative | 121 (28.67) | 19 (5.23) |  | 135 (18.10) | 5 (12.82) |  |
 Positive | 301 (71.33) | 344 (94.77) |  | 611 (81.90) | 34 (87.18) |  |
CK-7 | Â | Â | 0.006 | Â | Â | 1.000 |
 Negative | 19 (5.79) | 3 (1.27) |  | 21 (3.94) | 1 (3.13) |  |
 Positive | 309 (94.21) | 234 (98.73) |  | 512 (96.06) | 31 (96.88) |  |
Ki67 | Â | Â | 0.083 | Â | Â | 0.528 |
 Negative | 37 (28.03) | 28 (40.00) |  | 60 (31.58) | 5 (41.67) |  |
 Positive | 95 (71.97) | 42 (60.00) |  | 130 (68.42) | 7 (58.33) |  |